(Total Views: 453)
Posted On: 01/22/2020 1:38:03 PM
Post# of 145890
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
SRRA... following reverse stock split... Gilead Sciences, Inc. (Gilead) will be issued approximately 725,000 shares of common stock (on a post-split basis) and a warrant to purchase an equivalent amount of common stock, in consideration for amending the royalty rates and milestones in an Asset Purchase Agreement with Gilead for momelotinib.
PR: https://finance.yahoo.com/news/sierra-oncolog...00366.html
Gilead is getting into oncology. Can someone please elaborate on what SRRA has and comparison to CYDY.
I understand their product is second in line, for some cancers, and they are expecting Phase 3 data Q4 2021, and still a lot of uncertainties.
PR: https://finance.yahoo.com/news/sierra-oncolog...00366.html
Gilead is getting into oncology. Can someone please elaborate on what SRRA has and comparison to CYDY.
I understand their product is second in line, for some cancers, and they are expecting Phase 3 data Q4 2021, and still a lot of uncertainties.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)